20,400 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Bought by Stonepine Capital Management LLC

Stonepine Capital Management LLC acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 20,400 shares of the specialty pharmaceutical company's stock, valued at approximately $1,128,000. ANI Pharmaceuticals accounts for about 0.9% of Stonepine Capital Management LLC's portfolio, making the stock its 28th largest position. Stonepine Capital Management LLC owned 0.10% of ANI Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Millennium Management LLC increased its position in ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock worth $55,437,000 after buying an additional 473,097 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in ANI Pharmaceuticals by 4.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after purchasing an additional 30,420 shares during the period. Deep Track Capital LP boosted its position in ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock worth $35,879,000 after purchasing an additional 144,214 shares during the period. Global Alpha Capital Management Ltd. increased its stake in shares of ANI Pharmaceuticals by 16.4% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock worth $34,525,000 after purchasing an additional 88,100 shares in the last quarter. Finally, William Blair Investment Management LLC raised its position in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock valued at $26,826,000 after purchasing an additional 10,440 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ANIP. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target for the company. Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Truist Financial increased their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. Finally, Jefferies Financial Group began coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Stock Up 0.3%

ANIP stock traded up $0.20 during trading on Friday, hitting $57.47. 85,167 shares of the stock traded hands, compared to its average volume of 330,158. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -104.49 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $77.00. The firm's 50 day moving average is $66.62 and its two-hundred day moving average is $60.80.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. During the same period in the prior year, the company posted $0.82 earnings per share. The company's quarterly revenue was up 43.4% on a year-over-year basis. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. The trade was a 0.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the sale, the senior vice president now directly owns 89,897 shares of the company's stock, valued at $5,400,112.79. This represents a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,681 shares of company stock valued at $408,498 over the last three months. Insiders own 11.10% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.